Verition Fund Management
AVBP icon

Verition Fund Management’s ArriVent BioPharma AVBP Stock Holding History

Verition Fund Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,045
Closed -$278K – 4021
2025
Q3 		$278K Sell
15,045
-41,457
-73% -$814K ﹤0.01% 3335
2025
Q2 		$1.23M Buy
+56,502
New +$1.17M 0.01% 2312

Other funds holding AVBP

IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Verition Fund Management's AVBP Position: Q4 2025 in Review

Verition Fund Management sold out of ArriVent BioPharma (AVBP) in Q4 2025, closing a stake of 15,045 shares — an estimated $278K sold.

Verition Fund Management first reported a position in AVBP in Q2 2025 and held it in 2 quarters. The position peaked at $1.23M in Q2 2025. 121 funds tracked by Wall St. Rank hold AVBP as of Q4 2025.

  • Verition Fund Management reported no remaining ArriVent BioPharma position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 15,045 ArriVent BioPharma shares in Q4 2025, an estimated $278K.
  • Verition Fund Management first reported a position in ArriVent BioPharma in Q2 2025 and held it in 2 quarters.
  • Verition Fund Management's ArriVent BioPharma position peaked at $1.23M in Q2 2025.
  • 121 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.